I am the host of B Heppy, a podcast by the Hepatitis B Foundation. I am going to interview someone from pharma to discuss the process of hepatitis B drug development. I was wondering if anyone had any specific questions about this topic and if there is anything you would want to know from this episode.
I have the pre-S mutant which is more dangerous and importantly resistant to the antibody developed from current vaccine (I took Engerix B). This mutation have a high prevalence (18.3%), up to 36% in certain countries: https://doi.org/10.1128/jcm.41.12.5449-5455.2003 .
I wonder if this variant of the virus is taken into account for future drug development?
Thank you! I will be sure to include this.
hi @apatient we asked your question on the podcast episode about drug development - please find your answer here: Buzzsprout » The best way to create and publish a podcast
Tell them patience is running out. THE CURE IS NEEDED ASAP!!!